Drugs / 90Y DOTATATE
last change Jan 2021 re-read 2 minutes ago

90Y DOTATATE

Developed for
neuroendocrine neoplasm

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04029428 Comparator Nov 2004 → Jan 2021 neuroendocrine neoplasm University of Warmia and Mazury Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 90Y DOTATATE “Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids...” NCT04029428
Route Intravenous “Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump” NCT04029428